Gueudry Julie, Leclercq Mathilde, Saadoun David, Bodaghi Bahram
Department of Ophthalmology, Hôpital Charles Nicolle, F-76000 Rouen, France.
Department of Internal Medicine, Hôpital Charles Nicolle, F-76000 Rouen, France.
J Clin Med. 2021 May 26;10(11):2318. doi: 10.3390/jcm10112318.
Behçet's disease (BD) is a systemic vasculitis disease of unknown origin occurring in young people, which can be venous, arterial or both, classically occlusive. Ocular involvement is particularly frequent and severe; vascular occlusion secondary to retinal vasculitis may lead to rapid and severe loss of vision. Biologics have transformed the management of intraocular inflammation. However, the diagnosis of BD is still a major challenge. In the absence of a reliable biological marker, diagnosis is based on clinical diagnostic criteria and may be delayed after the appearance of the onset sign. However, therapeutic management of BD needs to be introduced early in order to control inflammation, to preserve visual function and to limit irreversible structural damage. The aim of this review is to provide current data on how innovations in clinical evaluation, investigations and treatments were able to improve the prognosis of uveitis associated with BD.
白塞病（BD）是一种发生于年轻人的病因不明的系统性血管炎疾病，可累及静脉、动脉或两者，典型表现为闭塞性病变。眼部受累尤为常见且严重；视网膜血管炎继发的血管闭塞可能导致迅速且严重的视力丧失。生物制剂改变了眼内炎症的治疗方式。然而，BD的诊断仍然是一项重大挑战。在缺乏可靠生物标志物的情况下，诊断基于临床诊断标准，且在发病体征出现后可能会延迟。然而，BD的治疗管理需要尽早开展，以控制炎症、保护视觉功能并限制不可逆的结构损伤。本综述的目的是提供有关临床评估、检查和治疗方面的创新如何能够改善BD相关葡萄膜炎预后的当前数据。
